[177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney

Christina Swärd,Peter Bernhardt,H. Ahlman,Bo Wängberg,Eva Forssell-Aronsson,Maria Larsson,Johanna Svensson,Rauni Rossi Norrlund,Lars Kölby

[177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney

2010

Christina Swärd
Peter Bernhardt
H. Ahlman
Bo Wängberg
Eva Forssell-Aronsson
Maria Larsson
Johanna Svensson
Rauni Rossi Norrlund
Lars Kölby

Background Peptide receptor radiation therapy (PRRT) using [177Lu-DOTA0-Tyr3]-octreotate is a new, promising option for treatment of disseminated gastroenteropancreatic neuroendocrine tumors (GEPNETs).

Keywords:

Renal function
Oncology
Chromogranin A
Absorbed dose
Surgery
Neuroendocrine tumors
Radiation therapy
Progressive disease
Octreotide
Medicine
Pathology
Kidney
Internal medicine
177Lu-DOTA0-Tyr3-Octreotate
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations